HDAC9 and plasma cell myeloma: Additional trials should focus on panobinostat's ability to resensitize multiple myeloma patients refractory/relapsed to second-generation IMIDs, newer proteasome inhibitors, and monoclonal antibodies, besides its ability to augment their therapeutic efficacy [87], as reported with other HDAC inhibitors [107–109].